Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2007-11-19
2009-11-17
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S560000, C424S523000
Reexamination Certificate
active
07619002
ABSTRACT:
The use of polyunsaturated fatty acids of the .omega.-3 series such as eicosapentaenoic acid (EPA, C.sub.20:5 .omega.-3), docosahexaenoic acid (DHA, C.sub.22:6 .omega.-3), or their pharmaceutically acceptable derivatives is described for the primary prevention of major cardiovascular events in subjects who have not undergone previous infarct episodes.
REFERENCES:
patent: 5130061 (1992-07-01), Cornieri et al.
patent: 5378732 (1995-01-01), Horrobin et al.
patent: 5502077 (1996-03-01), Breivik et al.
patent: 5541225 (1996-07-01), Leaf et al.
patent: 5656667 (1997-08-01), Breivik et al.
patent: 5698594 (1997-12-01), Breivik et al.
patent: 5753703 (1998-05-01), Cavazza et al.
patent: 5760081 (1998-06-01), Leaf et al.
patent: 5776978 (1998-07-01), Burzzese
patent: 5859055 (1999-01-01), Horrobin et al.
patent: 5869714 (1999-02-01), Burzzese
patent: 6008248 (1999-12-01), Pscherer et al.
patent: 6245811 (2001-06-01), Horrobin et al.
patent: 6284268 (2001-09-01), Mishra et al.
patent: 6670396 (2003-12-01), Serhan et al.
patent: 2003/0144219 (2003-07-01), Phinney et al.
patent: 2004/0162349 (2004-08-01), Shibuya
patent: 1082909 (1994-03-01), None
patent: 0409903 (1992-04-01), None
patent: 0 780 124 (1997-06-01), None
patent: 1 157 692 (2001-11-01), None
patent: 1157692 (2005-10-01), None
patent: 02/25447 (1988-07-01), None
patent: WO89/11521 (1989-11-01), None
patent: WO 00/32210 (2000-06-01), None
patent: WO00/48592 (2000-08-01), None
patent: WO 01/46115 (2001-06-01), None
patent: WO 01/60778 (2001-08-01), None
patent: WO02/058793 (2002-08-01), None
patent: WO 2008/066745 (2008-06-01), None
R. Pakala, et al., Atherosclerosis 153, XP-002229283, pp. 47-57, ‘Vascular Smooth Muscle Cells Preloaded With Eicosapentaenoic Acid and Docosahexaenoic Acid Fail to Respond to Serotonin Stimulation’, 2000.
S. Takeo. at al,, Molecular and Cellular Biochemistry 188, XP-008012809, pp. 199-208, Effects of Long-Term Treatment With Eicosapentaenoic Acid and Docosahexaenoic Acid Fail to Respond to Erotonin Stimulation 2000.
R. B. Singh, et al., Cardiovascular Drugs and Therapy 11, XP-008012824, pp. 485-491, Randomized, Double-Blind Placebo-Controlled Trial of Fish Oil and Mustard Oil in Patients With Suspected Acute Myocardial Infarction: The Indian Experiment of Infarct Survival 1997.
E. Guallar, et al., Arteriosclerosis, Thrombosis, and Vascular Biology 19, XP-001134928, pp. 1111-1118, ‘Omega-3 Fatty Acids in Adipose Tissue and Risk of Myocardial Infarction: The Euramic Study’, 1999.
P. McLennan, et al., European Journal of Pharmacology 300, XP-001134929, pp. 83-89, The Cardiovascular Protective Role of Docosahexaenoic Acid, 1996.
T. Rissanen, at al., Circulation, vol. 102, No. 22, XP-001134935, pp. 2677-2679, ‘Fish Oil-Derived Fatty Acids, and the Risk of Acute Coronary Events’, Docosahexaenoic Acid and Docosapentaenoic Acid, Nov. 28, 2000.
T. H. Rissanen, et al., Circulation, vol. 98, No. 17, XP-008012807, p. 2823, “Fish Oil-Derived Fatty Acids, Docosahexaenoic Acid and Docosapentaenoic Acid, and the Risk of Acute Myocardial, Infarction”, Oct. 27, 1998.
Harrison's Principles of Internal Medicine, 13th Ed., vol. 1, published 1994 by McGraw-Hill, Inc. (NY), pp. 1108-1116.
The Merck Manual of Diagnosis and Therapy, 14th Ed., published 1982 by Merck, Sharp & Dohme Research Laboratories (NJ), pp. 386-389 and 1036-1053.
EP 1157692B1 Notice of Opposition by IBSA Institut Biochimique S.A., Jul. 5, 2006, pp. 1-12 (e.g., pp. 9-10, section C).
EP 1157692B1 Notice of Opposition by Pronova Biocare A.S., Jul. 5, 2006, pp. 1-24 ( e.g. p. 22, section 3.17).
EP 1157692B1 Contestment of Opposition by Pro Aparts-Investimentos e Consultoria LDA, Apr. 11, 2007, pp. 1-24 and Annex 1 pp. 1-7, Annex 2, pp. 1-7, Annex 3 pp. 1-7, Annex 4 pp. 1-7 (e.g., p. 3 section 5; p. 15 section 9.3; pp. 23-24, section 9.4.8).
European Search Report for EP Application No. 02023126.
L. Frost et al.; n-3 Fatty acids consumed from fish and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study; Am J Clin Nutr 2005; 81:50-4.
Jahangiri, et al., “Restoration of Synchronous Contractile Activity by n-3 PUFAs in Atrial Cardiomyocytes”, Journal of Molecular and Cellular Cardiology, vol. 31, No. 1, A6 (1999).
Jahangiri, et al., “Termination of Asynchronous Contractile Activity in Rat Atrial Myocytes by n-3 Polyunsaturated Fatty Acids”, Molecular and Cellular Biochemistry, vol. 206, pp. 33-41 (Mar. 2000).
J. Kang and A. Leaf, “Protective Effects of Free Polyunsaturated Fatty Acids on Arrhythmias Induced by Lysophosphatidylcholine or Pamitoylcarnitine in Neonatal Rat Cardiac Myocytes”, European Journal of Pharmacology, vol. 297, No. 1-2, pp. 97-106 (1996).
Maixent, et al., “Remodeling of Na, K-ATPase, and Membrane Fluidity After Atrial Fibrillation in Sheep”, Journal of Receptors and Signal Transduction, vol. 22, Nos. 1-4, pp. 201-211 (2002; online publication date Jan. 12, 2002).
D. Mozaffarian et al.; Fish intake and risk of incident atrial fibrillation; Circulation 2004; Jul. 27; 110(4):368-73.
T. Rissanen, et al. Circulation, vol. 102, No. 22, XP-001134935, pp. 2677-2679, “Fish Oil Derived Fatty Acids, Docosahexaenoic Acid and Docosapentaenoic Acid, and the Risk of Acute Coronary Events, ” Nov. 28, 2000.
Siclari, et al., “Long Chain n 3 Fatty Acids Can Prevent Paroxysmal Atrial Fibrillation”, Circulation, vol. 106, No. 19 Suppl., pp. II 635 (Nov. 5, 2002). (See also Declaration of Cordelia Slaughter, below).
Declaration of Cordelia Slaughter, dated Nov. 28, 2006, regarding Siclari et al., “Long Chain n 3 Fatty Acids Can Prevent Paroxysmal Atrial Fibrillation”, Circulation, vol. 106, No. 19 Suppl. pp. II 635.
Swann et al., Clinical Drug Investigation 15 (6), 473-482, 1998.
S. Takeo, et al. Molecular and Cellular Biochemistry 188 XP-008012809, pp. 199-208, “Effects of Long-Term Treatment with Eicosapentaenoic Acid on the Heart Subjected to Ischemia/Reperfusion and Hypoxia/Reoxygenation in Rats”, 1998.
Arent & Fox LLP
Henley, III Raymond J
Pro Aparts Investimentos E Consultoria LDA. AV. Arriaga
LandOfFree
Use of polyunsaturated fatty acids for the primary... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of polyunsaturated fatty acids for the primary..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of polyunsaturated fatty acids for the primary... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4095656